Explore more publications!
East Timor Technology Press
Got News to Share?

East Timor Technology Press: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on East Timor Technology Press.

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

February 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28

March 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31

Press releases published on February 20, 2026

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
Feb. 20, 2026

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

Indeterminate GlobeNewswire
Constellation Software Inc. Announces Change to the Date of the Conference Call to Discuss Fourth Quarter Results
Feb. 20, 2026

Constellation Software Inc. Announces Change to the Date of the Conference Call to Discuss Fourth Quarter Results

Indeterminate GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Feb. 20, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Bel Fuse Inc. Announces Regular Quarterly Cash Dividend on its Class A and Class B Shares
Feb. 20, 2026

Bel Fuse Inc. Announces Regular Quarterly Cash Dividend on its Class A and Class B Shares

Indeterminate GlobeNewswire
GreenBanana SEO celebrates 30th 5-star Google Review, Reinforcing Role as Best Generative Engine Optimization (GEO) Agency
Feb. 20, 2026

GreenBanana SEO celebrates 30th 5-star Google Review, Reinforcing Role as Best Generative Engine Optimization (GEO) Agency

Indeterminate GlobeNewswire
iPower Reports Fiscal Q2 2026 Results and Completes Strategic Operating Reset
Feb. 20, 2026

iPower Reports Fiscal Q2 2026 Results and Completes Strategic Operating Reset

Indeterminate GlobeNewswire
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb. 20, 2026

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Feb. 20, 2026

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb. 20, 2026

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Foresight Announced ADS Ratio Change
Feb. 20, 2026

Foresight Announced ADS Ratio Change

Indeterminate GlobeNewswire
Averin Capital Acquisition Corp. Completes $250,000,000 Initial Public Offering
Feb. 20, 2026

Averin Capital Acquisition Corp. Completes $250,000,000 Initial Public Offering

Indeterminate GlobeNewswire
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb. 20, 2026

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
Feb. 20, 2026

Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates

Indeterminate GlobeNewswire
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
Feb. 20, 2026

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

Indeterminate GlobeNewswire
Inscope Raises $14.5M Series A to Replace Manual Financial Statement Preparation for Accounting Firms and Enterprises
Feb. 20, 2026

Inscope Raises $14.5M Series A to Replace Manual Financial Statement Preparation for Accounting Firms and Enterprises

Indeterminate GlobeNewswire
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Feb. 20, 2026

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Indeterminate GlobeNewswire
Sadhguru Presents Innovative AI Hologram Tech at Massive Event
Feb. 20, 2026

Sadhguru Presents Innovative AI Hologram Tech at Massive Event

Indeterminate GlobeNewswire
Media87 Named 2026’s Top Digital Marketing Agency and Local SEO Leader
Feb. 20, 2026

Media87 Named 2026’s Top Digital Marketing Agency and Local SEO Leader

Indeterminate GlobeNewswire
ESET’s Ryan Grant Named a 2026 CRN Channel Chief
Feb. 20, 2026

ESET’s Ryan Grant Named a 2026 CRN Channel Chief

Indeterminate GlobeNewswire
Photonic Inc. Appoints New Executive Chair and Four New Directors to its Board of Directors
Feb. 20, 2026

Photonic Inc. Appoints New Executive Chair and Four New Directors to its Board of Directors

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions